Yamanouchi and partner Boehringer Ingelheim have launched their prostate-selective alpha1 blocker tamsulosin in France, as Omix LP and Josir LP respectively. The products, indicated for the treatment of benign prostatic hypertrophy, come in boxes of 30 gel capsules at a cost of 187.20 French francs ($36.19) per pack. They are 35% reimbursable through French social security.
Tamsulosin is pending approval in the USA, and has already been cleared in several other countries, including Japan, Holland, Denmark, Finland and the UK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze